Skip to main content
TipRanks
Go Ultimate75% OFF

Equillium (0FY) AI Stock Analysis

0 Followers
DE:0FY

Equillium

(Frankfurt:0FY)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low LeverageMinimal debt reduces financing pressure and preserves flexibility while Equillium funds clinical development. The increases in equity and assets versus 2025 provide a stronger capital base, although that base has not yet generated positive returns.
Negative Factors
Absent Recent RevenueThe complete absence of recent revenue weakens earnings visibility and shows that Equillium is not currently funding operations through commercial sales. Until revenue returns, financial progress remains dependent on clinical milestones and access to external capital.

Equillium (0FY) vs. iShares MSCI Germany ETF (EWG)

-50%0%50%100%150%200%250%DE:0FY+46.42%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 81.80M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-7.3
Beta (1Y)
-1.33
Revenue Growth
-100.00%
EPS Growth
73.50%
Country
Germany
Employees
14
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Equillium Business Overview & Revenue Model

Company Description

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficien...

Equillium Risk Analysis

Equillium disclosed 86 risk factors in its most recent earnings report. Equillium reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Risk factors summaryQ2, 2026
2.Risks Related to Our Financial Position and Need for Additional CapitalQ2, 2026
3.Risks Related to our Business and to the Development and Regulatory Approval of our Product CandidatesQ2, 2026

Equillium Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:0FY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NRXPNRXP46Neutral$95.59M-2.95168.68%――67.07%
HYFTHYFT45Neutral$47.10M-3.87-144.31%―-26.89%56.50%
STROSTRO42Neutral$163.03M-0.78142.71%―-57.30%51.45%
PRLDPRLD38Underperform$275.32M-4.37-75.35%―220.34%55.73%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%DE:0FYNRXPSTROHYFTPRLDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:0FY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:0FYEquillium1.210.5071.65%
NRXPNrx Pharmaceuticals, Inc.2.190.083.79%
STROSutro Biopharma9.821.3215.53%
HYFTMindwalk Holdings Corp.0.99-0.73-42.44%
PRLDPrelude Therapeutics, Inc.3.451.80109.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.